Paul Bessette
Overview
Explore the profile of Paul Bessette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1209
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Plante M, Mahner S, Sebastianelli A, Bessette P, Lambaudie E, Guyon F, et al.
Int J Gynecol Cancer
. 2025 Jan;
35(1):100001.
PMID: 39878257
Objective: The Laparoscopic Approach to Cervical Cancer trial demonstrated that minimally invasive radical hysterectomy was associated with worse disease-free survival and overall survival among women with early-stage cervical cancer. It...
2.
IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Moynihan K, Kumar M, Sultan H, Pappas D, Park T, Chin S, et al.
Cancer Discov
. 2024 Apr;
14(7):1206-1225.
PMID: 38563906
IL2 signals pleiotropically on diverse cell types, some of which contribute to therapeutic activity against tumors, whereas others drive undesired activity, such as immunosuppression or toxicity. We explored the theory...
3.
Kaya M, Post C, Tops C, Nielsen M, Crosbie E, Leary A, et al.
Mod Pathol
. 2024 Jan;
37(3):100423.
PMID: 38191122
Universal tumor screening in endometrial carcinoma (EC) is increasingly adopted to identify individuals at risk of Lynch syndrome (LS). These cases involve mismatch repair-deficient (MMRd) EC without MLH1 promoter hypermethylation...
4.
Cyr M, Camden C, Dumoulin C, Dostie R, Bessette P, Pina A, et al.
Arch Sex Behav
. 2023 Apr;
52(6):2669-2681.
PMID: 37058221
Pain during sexual intercourse, also called dyspareunia, affects most women after treatment for gynecological cancer. Previous work adopted a biomedical approach to depict dyspareunia in this population, which provided a...
5.
Cyr M, Dostie R, Camden C, Dumoulin C, Bessette P, Pina A, et al.
Int Urogynecol J
. 2022 Aug;
34(5):1061-1073.
PMID: 35947187
Introduction And Hypothesis: Multimodal pelvic floor physical therapy (PFPT) is recommended after gynecological malignancies to treat dyspareunia. However, data to strongly support its implementation in the cancer care continuum are...
6.
Monk B, Parkinson C, Lim M, OMalley D, Oaknin A, Wilson M, et al.
J Clin Oncol
. 2022 Jun;
40(34):3952-3964.
PMID: 35658487
Purpose: ATHENA (ClinicalTrials.gov identifier: NCT03522246) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without or (BRCA) mutations or other evidence of homologous recombination...
7.
Cyr M, Dumoulin C, Bessette P, Pina A, Gotlieb W, Lapointe-Milot K, et al.
Physiotherapy
. 2022 Jan;
114:54-62.
PMID: 35093737
Objective: To investigate the changes in pelvic floor morphometry and muscle function after multimodal pelvic floor physiotherapy treatment in gynaecological cancer survivors suffering from painful intercourse (dyspareunia). Design: Prospective interventional...
8.
Cyr M, Dostie R, Camden C, Dumoulin C, Bessette P, Pina A, et al.
PLoS One
. 2022 Jan;
17(1):e0262844.
PMID: 35077479
Background: A large proportion of gynecological cancer survivors suffer from pain during sexual intercourse, also known as dyspareunia. Following a multimodal pelvic floor physical therapy (PFPT) treatment, a reduction in...
9.
Wortman B, Post C, Powell M, Khaw P, Fyles A, DAmico R, et al.
Int J Radiat Oncol Biol Phys
. 2021 Oct;
112(2):390-399.
PMID: 34610387
Purpose: Radiation therapy techniques have developed from 3-dimensional conformal radiation therapy (3DCRT) to intensity modulated radiation therapy (IMRT), with better sparing of the surrounding normal tissues. The current analysis aimed...
10.
Paquette M, Espinosa-Bentancourt E, Lavallee E, Phoenix S, Lapointe-Milot K, Bessette P, et al.
J Nucl Med
. 2021 Aug;
63(5):702-707.
PMID: 34413142
This article reports the preliminary results of a phase II clinical trial investigating the use of the estrogen receptor (ER)-targeting PET tracer 4-fluoro-11β-methoxy-16α-F-fluoroestradiol (F-4FMFES) and F-FDG PET in endometrial cancers....